News articles about United Therapeutics (NASDAQ:UTHR) have been trending somewhat positive on Saturday, according to AlphaOne Sentiment. The research group, a subsidiary of Accern, ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. United Therapeutics earned a coverage optimism score of 0.02 on AlphaOne’s scale. AlphaOne also assigned news headlines about the biotechnology company an impact score of 81 out of 100, meaning that recent press coverage is very likely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted AlphaOne Sentiment Analysis’s analysis:
- UNITED THERAPEUTICS CORP : Entry into a Material Definitive Agreement (form 8-K) (4-traders.com)
- FY2021 EPS Estimates for United Therapeutics Co. Reduced by Analyst (UTHR) (americanbankingnews.com)
- Blog Coverage: Ionis Pharma Reported Positive Phase III Results in Patients with Familial Amyloid Polyneuropathy (finance.yahoo.com)
- Insider Trading Activity United Therapeutics Co. (NASDAQ:UTHR) – CEO Sold 1,259 shares of Stock (4-traders.com)
- ETFs with exposure to United Therapeutics Corp. : May 15, 2017 (finance.yahoo.com)
Several analysts recently issued reports on the company. Oppenheimer Holdings Inc. restated a “buy” rating on shares of United Therapeutics in a research note on Monday, April 3rd. Cowen and Company restated a “hold” rating and issued a $121.00 price target on shares of United Therapeutics in a research note on Wednesday, April 26th. Jefferies Group LLC downgraded United Therapeutics from a “hold” rating to an “underperform” rating and reduced their price target for the company from $149.47 to $116.00 in a research note on Monday, March 6th. Wedbush reiterated an “outperform” rating and set a $229.00 target price on shares of United Therapeutics in a research report on Friday, January 27th. Finally, HC Wainwright reiterated a “hold” rating and set a $95.00 target price on shares of United Therapeutics in a research report on Monday, April 17th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the stock. United Therapeutics has a consensus rating of “Hold” and a consensus price target of $135.17.
United Therapeutics (NASDAQ:UTHR) opened at 121.64 on Friday. The firm has a market cap of $5.48 billion, a PE ratio of 8.54 and a beta of 1.42. The stock’s 50 day moving average price is $122.63 and its 200-day moving average price is $138.59. United Therapeutics has a 12-month low of $97.52 and a 12-month high of $169.89.
United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, April 26th. The biotechnology company reported $3.89 EPS for the quarter, beating the consensus estimate of $3.12 by $0.77. United Therapeutics had a net margin of 44.40% and a return on equity of 41.78%. The business had revenue of $370.50 million during the quarter, compared to the consensus estimate of $399.59 million. During the same quarter in the prior year, the firm earned $3.02 EPS. The business’s revenue was up .4% on a year-over-year basis. Equities research analysts anticipate that United Therapeutics will post $14.42 earnings per share for the current fiscal year.
In other United Therapeutics news, CEO Martine A. Rothblatt sold 1,208 shares of the stock in a transaction dated Thursday, February 23rd. The shares were sold at an average price of $145.16, for a total transaction of $175,353.28. Following the completion of the transaction, the chief executive officer now owns 1,348 shares of the company’s stock, valued at approximately $195,675.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Tommy G. Thompson sold 2,000 shares of the stock in a transaction dated Wednesday, March 22nd. The shares were sold at an average price of $139.37, for a total transaction of $278,740.00. Following the completion of the transaction, the director now directly owns 2,000 shares of the company’s stock, valued at approximately $278,740. The disclosure for this sale can be found here. Insiders have sold a total of 16,838 shares of company stock valued at $2,235,646 in the last three months. Insiders own 7.50% of the company’s stock.
WARNING: This news story was first reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://transcriptdaily.com/2017/05/20/somewhat-favorable-media-coverage-very-likely-to-affect-united-therapeutics-uthr-stock-price-updated-updated.html.
United Therapeutics Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co. and related companies with MarketBeat.com's FREE daily email newsletter.